Loading…
Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening
Background. There are no effective means for screening for lung cancer, so the authors assessed the utility of four lung cancer tumor markers for screening. Methods. A case–control study, nested in a cohort study based on the linkage of records of health survey examinees with Finnish Cancer Registry...
Saved in:
Published in: | Cancer 1993-03, Vol.71 (6), p.1982-1988 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c4140-1c8ba520ed69259c3f6566f9082cd12c8bb33386b04d0af719b283189f82abb03 |
container_end_page | 1988 |
container_issue | 6 |
container_start_page | 1982 |
container_title | Cancer |
container_volume | 71 |
creator | Järvisalo, Jorma Hakama, Matti Knekt, Paul Stenman, Ulf‐Håkan Leino, Aila Teppo, Lyly Maatela, Jouni Aromaa, Arpo |
description | Background. There are no effective means for screening for lung cancer, so the authors assessed the utility of four lung cancer tumor markers for screening.
Methods. A case–control study, nested in a cohort study based on the linkage of records of health survey examinees with Finnish Cancer Registry records, was used to test the validity of tumor markers carcinoembryonic antigen (CEA), tumor‐associated trypsin inhibitor (TATI), neuron‐specific enolase (NSE), and CA 50 in lung cancer screening. Ten years after health examinations, record linkage indicated that 187 men had lung cancer; 344 control subjects, matched for age, sex, and municipality were drawn from the same records.
Results. The data allowed assessment of the sensitivity of the marker assays at a 95% specificity level, which was highest for CEA (17% at a concentration level of 5.3 μg/l). Logistic discrimination analysis indicated that of the other markers, only TATI, when used in combination, improved the discriminatory power of CEA. CEA and TATI levels correlated significantly with smoking. They also showed a significant gradient toward increasing risk of lung cancer from the lowest to the highest quintiles of marker levels (for CEA, crude relative risk between the highest and lowest quintiles, 8.6). The gradient also was evident in the subgroup whose cancer had been diagnosed more than 5 years after serum specimen collection. The trend persisted, although relative risk was halved after adjustment for smoking.
Conclusions. The markers do not seem to be useful tools for lung cancer screening. However, CEA and TATI levels seem to give information on cancer risk long before the clinical cancer stage, as the quintile‐based analyses of marker levels indicate. |
doi_str_mv | 10.1002/1097-0142(19930315)71:6<1982::AID-CNCR2820710610>3.0.CO;2-G |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75603073</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75603073</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4140-1c8ba520ed69259c3f6566f9082cd12c8bb33386b04d0af719b283189f82abb03</originalsourceid><addsrcrecordid>eNqVkF1r2zAYhcVY6bJuP2GgizE2iLNXH5albAyMl6aB0sCawWAXL7IsF2-200k1o_9-DkkD3cVgV0KcR4ejh5CCwYwB8PcMTJYAk_wtM0aAYOm7jM3VR2Y0n8_z1eekuCq-cM0hY6AYfBIzmBXrDzxZPiGT4-unZAIAOkml-PaMPI_xx3jNeCpOyamWUmTSTMj5tQ9DR--GbhtoZ8NPHyItFvmUFjlNYUo3-WY1pbav6NX1gjY9bYf-hjrbOx9odMH7vulvXpCT2rbRvzycZ-Tr-WJTXCSX6-WqyC8TJ5mEhDld2pSDr5ThqXGiVqlStQHNXcX4mJZCCK1KkBXYOmOm5FowbWrNbVmCOCNv9r23Yftr8PEOuyY637a299shYpYqEJCJEfy-B13Yxhh8jbehGf93jwxwZxl3nnDnCR8sY8ZQ4c4y4mgZH1tGgYDFGjkux_ZXhxlD2fnq2H3QOuavD7mNzrZ1GHU18YhJJRnIdMTqPfa7af39_y3858C_EvEHiTSiQA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75603073</pqid></control><display><type>article</type><title>Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening</title><source>Free E-Journal (出版社公開部分のみ)</source><creator>Järvisalo, Jorma ; Hakama, Matti ; Knekt, Paul ; Stenman, Ulf‐Håkan ; Leino, Aila ; Teppo, Lyly ; Maatela, Jouni ; Aromaa, Arpo</creator><creatorcontrib>Järvisalo, Jorma ; Hakama, Matti ; Knekt, Paul ; Stenman, Ulf‐Håkan ; Leino, Aila ; Teppo, Lyly ; Maatela, Jouni ; Aromaa, Arpo</creatorcontrib><description>Background. There are no effective means for screening for lung cancer, so the authors assessed the utility of four lung cancer tumor markers for screening.
Methods. A case–control study, nested in a cohort study based on the linkage of records of health survey examinees with Finnish Cancer Registry records, was used to test the validity of tumor markers carcinoembryonic antigen (CEA), tumor‐associated trypsin inhibitor (TATI), neuron‐specific enolase (NSE), and CA 50 in lung cancer screening. Ten years after health examinations, record linkage indicated that 187 men had lung cancer; 344 control subjects, matched for age, sex, and municipality were drawn from the same records.
Results. The data allowed assessment of the sensitivity of the marker assays at a 95% specificity level, which was highest for CEA (17% at a concentration level of 5.3 μg/l). Logistic discrimination analysis indicated that of the other markers, only TATI, when used in combination, improved the discriminatory power of CEA. CEA and TATI levels correlated significantly with smoking. They also showed a significant gradient toward increasing risk of lung cancer from the lowest to the highest quintiles of marker levels (for CEA, crude relative risk between the highest and lowest quintiles, 8.6). The gradient also was evident in the subgroup whose cancer had been diagnosed more than 5 years after serum specimen collection. The trend persisted, although relative risk was halved after adjustment for smoking.
Conclusions. The markers do not seem to be useful tools for lung cancer screening. However, CEA and TATI levels seem to give information on cancer risk long before the clinical cancer stage, as the quintile‐based analyses of marker levels indicate.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/1097-0142(19930315)71:6<1982::AID-CNCR2820710610>3.0.CO;2-G</identifier><identifier>PMID: 8443749</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Antigens, Tumor-Associated, Carbohydrate - blood ; Biological and medical sciences ; Biomarkers, Tumor - blood ; CA 50 ; carcinoembryonic antigen ; Carcinoembryonic Antigen - blood ; Female ; human serum ; Humans ; lung cancer screening ; Lung Neoplasms - blood ; Male ; Medical sciences ; neuron‐specific enolase ; Phosphopyruvate Hydratase - blood ; Pneumology ; register linkage study ; Sensitivity and Specificity ; Trypsin Inhibitor, Kazal Pancreatic - blood ; tumor markers ; Tumors of the respiratory system and mediastinum ; tumor‐associated trypsin inhibitor</subject><ispartof>Cancer, 1993-03, Vol.71 (6), p.1982-1988</ispartof><rights>Copyright © 1993 American Cancer Society</rights><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4140-1c8ba520ed69259c3f6566f9082cd12c8bb33386b04d0af719b283189f82abb03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4641045$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8443749$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Järvisalo, Jorma</creatorcontrib><creatorcontrib>Hakama, Matti</creatorcontrib><creatorcontrib>Knekt, Paul</creatorcontrib><creatorcontrib>Stenman, Ulf‐Håkan</creatorcontrib><creatorcontrib>Leino, Aila</creatorcontrib><creatorcontrib>Teppo, Lyly</creatorcontrib><creatorcontrib>Maatela, Jouni</creatorcontrib><creatorcontrib>Aromaa, Arpo</creatorcontrib><title>Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Background. There are no effective means for screening for lung cancer, so the authors assessed the utility of four lung cancer tumor markers for screening.
Methods. A case–control study, nested in a cohort study based on the linkage of records of health survey examinees with Finnish Cancer Registry records, was used to test the validity of tumor markers carcinoembryonic antigen (CEA), tumor‐associated trypsin inhibitor (TATI), neuron‐specific enolase (NSE), and CA 50 in lung cancer screening. Ten years after health examinations, record linkage indicated that 187 men had lung cancer; 344 control subjects, matched for age, sex, and municipality were drawn from the same records.
Results. The data allowed assessment of the sensitivity of the marker assays at a 95% specificity level, which was highest for CEA (17% at a concentration level of 5.3 μg/l). Logistic discrimination analysis indicated that of the other markers, only TATI, when used in combination, improved the discriminatory power of CEA. CEA and TATI levels correlated significantly with smoking. They also showed a significant gradient toward increasing risk of lung cancer from the lowest to the highest quintiles of marker levels (for CEA, crude relative risk between the highest and lowest quintiles, 8.6). The gradient also was evident in the subgroup whose cancer had been diagnosed more than 5 years after serum specimen collection. The trend persisted, although relative risk was halved after adjustment for smoking.
Conclusions. The markers do not seem to be useful tools for lung cancer screening. However, CEA and TATI levels seem to give information on cancer risk long before the clinical cancer stage, as the quintile‐based analyses of marker levels indicate.</description><subject>Antigens, Tumor-Associated, Carbohydrate - blood</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>CA 50</subject><subject>carcinoembryonic antigen</subject><subject>Carcinoembryonic Antigen - blood</subject><subject>Female</subject><subject>human serum</subject><subject>Humans</subject><subject>lung cancer screening</subject><subject>Lung Neoplasms - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>neuron‐specific enolase</subject><subject>Phosphopyruvate Hydratase - blood</subject><subject>Pneumology</subject><subject>register linkage study</subject><subject>Sensitivity and Specificity</subject><subject>Trypsin Inhibitor, Kazal Pancreatic - blood</subject><subject>tumor markers</subject><subject>Tumors of the respiratory system and mediastinum</subject><subject>tumor‐associated trypsin inhibitor</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><recordid>eNqVkF1r2zAYhcVY6bJuP2GgizE2iLNXH5albAyMl6aB0sCawWAXL7IsF2-200k1o_9-DkkD3cVgV0KcR4ejh5CCwYwB8PcMTJYAk_wtM0aAYOm7jM3VR2Y0n8_z1eekuCq-cM0hY6AYfBIzmBXrDzxZPiGT4-unZAIAOkml-PaMPI_xx3jNeCpOyamWUmTSTMj5tQ9DR--GbhtoZ8NPHyItFvmUFjlNYUo3-WY1pbav6NX1gjY9bYf-hjrbOx9odMH7vulvXpCT2rbRvzycZ-Tr-WJTXCSX6-WqyC8TJ5mEhDld2pSDr5ThqXGiVqlStQHNXcX4mJZCCK1KkBXYOmOm5FowbWrNbVmCOCNv9r23Yftr8PEOuyY637a299shYpYqEJCJEfy-B13Yxhh8jbehGf93jwxwZxl3nnDnCR8sY8ZQ4c4y4mgZH1tGgYDFGjkux_ZXhxlD2fnq2H3QOuavD7mNzrZ1GHU18YhJJRnIdMTqPfa7af39_y3858C_EvEHiTSiQA</recordid><startdate>19930315</startdate><enddate>19930315</enddate><creator>Järvisalo, Jorma</creator><creator>Hakama, Matti</creator><creator>Knekt, Paul</creator><creator>Stenman, Ulf‐Håkan</creator><creator>Leino, Aila</creator><creator>Teppo, Lyly</creator><creator>Maatela, Jouni</creator><creator>Aromaa, Arpo</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19930315</creationdate><title>Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening</title><author>Järvisalo, Jorma ; Hakama, Matti ; Knekt, Paul ; Stenman, Ulf‐Håkan ; Leino, Aila ; Teppo, Lyly ; Maatela, Jouni ; Aromaa, Arpo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4140-1c8ba520ed69259c3f6566f9082cd12c8bb33386b04d0af719b283189f82abb03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Antigens, Tumor-Associated, Carbohydrate - blood</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>CA 50</topic><topic>carcinoembryonic antigen</topic><topic>Carcinoembryonic Antigen - blood</topic><topic>Female</topic><topic>human serum</topic><topic>Humans</topic><topic>lung cancer screening</topic><topic>Lung Neoplasms - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>neuron‐specific enolase</topic><topic>Phosphopyruvate Hydratase - blood</topic><topic>Pneumology</topic><topic>register linkage study</topic><topic>Sensitivity and Specificity</topic><topic>Trypsin Inhibitor, Kazal Pancreatic - blood</topic><topic>tumor markers</topic><topic>Tumors of the respiratory system and mediastinum</topic><topic>tumor‐associated trypsin inhibitor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Järvisalo, Jorma</creatorcontrib><creatorcontrib>Hakama, Matti</creatorcontrib><creatorcontrib>Knekt, Paul</creatorcontrib><creatorcontrib>Stenman, Ulf‐Håkan</creatorcontrib><creatorcontrib>Leino, Aila</creatorcontrib><creatorcontrib>Teppo, Lyly</creatorcontrib><creatorcontrib>Maatela, Jouni</creatorcontrib><creatorcontrib>Aromaa, Arpo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Järvisalo, Jorma</au><au>Hakama, Matti</au><au>Knekt, Paul</au><au>Stenman, Ulf‐Håkan</au><au>Leino, Aila</au><au>Teppo, Lyly</au><au>Maatela, Jouni</au><au>Aromaa, Arpo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1993-03-15</date><risdate>1993</risdate><volume>71</volume><issue>6</issue><spage>1982</spage><epage>1988</epage><pages>1982-1988</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>Background. There are no effective means for screening for lung cancer, so the authors assessed the utility of four lung cancer tumor markers for screening.
Methods. A case–control study, nested in a cohort study based on the linkage of records of health survey examinees with Finnish Cancer Registry records, was used to test the validity of tumor markers carcinoembryonic antigen (CEA), tumor‐associated trypsin inhibitor (TATI), neuron‐specific enolase (NSE), and CA 50 in lung cancer screening. Ten years after health examinations, record linkage indicated that 187 men had lung cancer; 344 control subjects, matched for age, sex, and municipality were drawn from the same records.
Results. The data allowed assessment of the sensitivity of the marker assays at a 95% specificity level, which was highest for CEA (17% at a concentration level of 5.3 μg/l). Logistic discrimination analysis indicated that of the other markers, only TATI, when used in combination, improved the discriminatory power of CEA. CEA and TATI levels correlated significantly with smoking. They also showed a significant gradient toward increasing risk of lung cancer from the lowest to the highest quintiles of marker levels (for CEA, crude relative risk between the highest and lowest quintiles, 8.6). The gradient also was evident in the subgroup whose cancer had been diagnosed more than 5 years after serum specimen collection. The trend persisted, although relative risk was halved after adjustment for smoking.
Conclusions. The markers do not seem to be useful tools for lung cancer screening. However, CEA and TATI levels seem to give information on cancer risk long before the clinical cancer stage, as the quintile‐based analyses of marker levels indicate.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>8443749</pmid><doi>10.1002/1097-0142(19930315)71:6<1982::AID-CNCR2820710610>3.0.CO;2-G</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0008-543X |
ispartof | Cancer, 1993-03, Vol.71 (6), p.1982-1988 |
issn | 0008-543X 1097-0142 |
language | eng |
recordid | cdi_proquest_miscellaneous_75603073 |
source | Free E-Journal (出版社公開部分のみ) |
subjects | Antigens, Tumor-Associated, Carbohydrate - blood Biological and medical sciences Biomarkers, Tumor - blood CA 50 carcinoembryonic antigen Carcinoembryonic Antigen - blood Female human serum Humans lung cancer screening Lung Neoplasms - blood Male Medical sciences neuron‐specific enolase Phosphopyruvate Hydratase - blood Pneumology register linkage study Sensitivity and Specificity Trypsin Inhibitor, Kazal Pancreatic - blood tumor markers Tumors of the respiratory system and mediastinum tumor‐associated trypsin inhibitor |
title | Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T09%3A41%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20tumor%20markers%20CEA,%20CA%2050,%20TATI,%20and%20NSE%20in%20lung%20cancer%20screening&rft.jtitle=Cancer&rft.au=J%C3%A4rvisalo,%20Jorma&rft.date=1993-03-15&rft.volume=71&rft.issue=6&rft.spage=1982&rft.epage=1988&rft.pages=1982-1988&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/1097-0142(19930315)71:6%3C1982::AID-CNCR2820710610%3E3.0.CO;2-G&rft_dat=%3Cproquest_cross%3E75603073%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4140-1c8ba520ed69259c3f6566f9082cd12c8bb33386b04d0af719b283189f82abb03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=75603073&rft_id=info:pmid/8443749&rfr_iscdi=true |